Nav: Home

New lipid-lowering drugs help patients reduce LDL cholesterol

August 01, 2016

A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

Mutations in the gene that encodes PCSK9 (proprotein convertase subtilisin/kexin type 9) have been linked to high cholesterol. PCSK9 causes elevated blood levels of LDL cholesterol because it binds to the LDL receptor. Two anti-PCSK9 antibodies have recently been approved by the US Food and Drug Administration and the European Medicines Agency: alirocumab and evolocumab.

Researchers identified 12 studies of alirocumab and nine of evolocumab, including more than 10,000 patients, most of whom were taking statins but still had elevated cholesterol. All studies demonstrated a reduction in LDL cholesterol with the anti-PCSK9 antibodies. Up to 87% of patients receiving alirocumab and up to 98% receiving evolocumab reached LDL cholesterol goals.

"Both anti-PSCK9 antibodies have cardiovascular outcome studies ongoing with results expected in 2017. We are looking forward to them since it is rather unusual to have results of large outcome trials so soon after the launch of a drug in the market," said Prof. Ioanna Gouni-Berthold, lead author of the British Journal of Clinical Pharmacology study.
-end-


Wiley

Related Evolocumab Articles:

PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function
New research led by the TIMI Study Group at Brigham and Women's Hospital in collaboration with Brown University and the University of Geneva reassuringly finds no association between the use of the PCSK9 inhibitor evolocumab and a decline in memory or cognitive function.
No evidence of cognitive issues when evolocumab added to statin therapy
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other problems with cognition or thinking, according to findings from the EBBINGHAUS study, the largest, most rigorously designed study to address this issue to date.
Evolocumab significantly reduces risk of cardiovascular events
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or 'bad' cholesterol, also significantly lowers the risk of cardiovascular events in patients with existing heart or vascular disease already on statin therapy, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.
PCSK9 inhibitor evolocumab reduces adverse cardiovascular events
Patients treated with evolocumab had a 15 percent reduction in the risk of major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization Evolocumab reduced the more serious key secondary endpoint, which was a composite of heart attack, stroke or cardiovascular death, by 20 percent.
Study suggests new drug alongside statins can significantly cut cholesterol
A new class of cholesterol-lowering drug has been found to help patients cut their risk of cardiovascular disease, stroke and heart attack.
PCSK9 inhibitior bococizumab produces varying results
Researchers report that bococizumab had short-term benefits on lowering cholesterol levels and significantly reduced the risk of cardiovascular events by 21 percent compared to placebo among those who had baseline LDL cholesterol levels of greater than 100 mg/dL.
Canadian Cardiovascular Society sets new guidelines for management of lipid metabolism disorders that affect cholesterol and cause atherosclerosis
The Canadian Cardiovascular Society has published an important update to its guidelines for the management of dyslipidemia -- lipid metabolism disorders -- that can cause cardiovascular disease.
Recently approved cholesterol medication not cost-effective; could substantially increase US health costs
Although the recently FDA-approved cholesterol-lowering drugs, PCSK9 inhibitors, could substantially reduce heart attacks, strokes, and cardiovascular deaths, they would not be cost-effective for use in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, with annual drug prices needing to be reduced by more than two-thirds to meet a generally acceptable threshold for cost-effectiveness, according to a study appearing in the Aug.
New lipid-lowering drugs help patients reduce LDL cholesterol
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.
Cholesterol lowering therapies for patients with muscle-related statin intolerance
Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab.

Related Evolocumab Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...